Author(s): Martin David Harp
Key Takeaways
- Vantage Biosciences has begun a phase 2 trial for VX-01, targeting moderate to severe NPDR without CI-DME.
- The study is double masked, randomized, placebo controlled, and involves a 52-week treatment and 12-week observation period.
- VX-01 is designed to target neurovascular inflammation, aiming to slow or prevent NPDR progression before vision loss.
- The trial is being conducted at 27 sites in the US, Australia, and Southeast Asia, with results expected in 2027.
Vantage Biosciences has successfully dosed the first patient in its phase 2 clinical study evaluating VX-01, an oral therapy for the treatment of nonproliferative diabetic retinopathy (NPDR).
VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study designed to evaluate the efficacy of an oral dose of VX-01 in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME). Participants will be randomly assigned 1:1 into 1 of 2 study cohorts and will take VX-01 or placebo twice daily for 52 consecutive weeks, followed by a 12-week post-treatment observation period.
VX-01 is an orally administered small-molecule therapy designed to target neurovascular inflammation associated with diabetic eye disease and aims to slow or prevent disease progression in patients with NPDR before irreversible vision loss occurs.
Read more: rb.gy/ianvqz
Source: Ophthalmology Times